Bright Green Corporation has announced its merger with PharmAGRI Capital Partners, a federally aligned pharmaceutical infrastructure platform architected to restore U.S. drug manufacturing sovereignty. The transaction consolidates BGXX’s DEA registrations, Board of Pharmacy licensure, audited financials, and Nasdaq history into PharmAGRI under a court-supervised restructuring plan filed in the District of New Mexico.
Effective immediately, Lynn Stockwell has been appointed Chief Executive Officer and Chairwoman of PharmAGRI. Stockwell will appoint a new board composed of directors from her Drugs Made In America Acquisition Corps—a series of four Nasdaq-listed special purpose acquisition companies (SPACs) formed to acquire DEA-licensed and FDA-compliant pharmaceutical businesses. Acquisition Corps I has completed an IPO and II is completing the SEC review, with Corps III and IV in formation to expand the platform’s reach and consolidate sovereign production assets.
PharmAGRI’s vertically integrated model executes “seed to syringe” drug manufacturing entirely on American soil, supporting EB-5 investor pathways, federal contract capture, and export of U.S.-manufactured controlled substances. As part of the merger, PharmAGRI will assume control of Bright Green LLC, a USCIS- EB-5 Regional Center applicant. The Regional Center will undergo a strategic realignment to support sovereign pharmaceutical infrastructure, robotics deployment, and high-wage job creation consistent with EB-5 program requirements.
PharmAGRI has executed a Letter of Intent (LOI) with Tesla to deploy up to 10,000 Optimus 3+ humanoid robotics across its owner-operator farm operations, API synthesis, and prescription drug manufacturing. The deployment is engineered for diversion control and DEA labor compliance, eliminating low-wage repetitive tasks and elevating the substantially reduced labor force into high-wage technical roles. It also ensures no reliance on undocumented labor, replacing historically exploited roles with robotics and retraining programs that support sovereign employment and wage elevation. The robotic are designed to meet all DEA and FDA compliance and are audit ready around-the-clock independently generating reports on global inventory, including standard operating procedures at any of the work stations.
